Surrozen, Inc./DE
Surrozen develops Wnt-based biologics for sight-threatening ophthalmic conditions.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 16Latest story
November 2026
October 2026
August 2026
Surrozen develops Wnt-based biologics for sight-threatening ophthalmic conditions.
November 2026
October 2026
August 2026